Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More